Exclusion Criteria
Patients were excluded from the study if: 1) dihydropyridine was indicated for a condition other than hypertension; 2) the patient never actually received felodipine; 3) there was documented noncompliance with medication or follow-up appointments for blood pressure evaluation in patient records; or 4) no pre-or post-conversion blood pressure data were available.
Vital Signs Technique
Biannually calibrated digital vital sign monitors or handheld sphygmomanometers were used to obtain patient blood pressure. Blood pressure and heart rate were determined using standard techniques of examination. Ambulatory care physi- 
Data Analysis
Blood pressure and heart rate values were averaged for up to three visits preconversion and post-conversion for each patient. The mean and standard deviation of systolic and diastolic blood pressure, as well as heart rates both preconversion and post-conversion, were determined. Continuous data were presented as the mean :t the standard deviation (SD Comorbidiy 
DISCUSSION
Numerous studies have demonstrated the efficacy, tolerability, and safety of dihydropyridine calcium channel blockers. I.' Blood pressure and heart rates obtained from related analyses were similar to those found in this study (see Table 2 ). The results of this study confirm that dihydropyridine felodipine extended release provides control of blood pressure and heart rate comparable to nifedipine extended release. A DBP controlled to <90 mm Hg was indicated since the benefits of treatment for diastolic hypertension in older individuals have been firmly established. The control of elevated DBP is also associated with a reduction in cardiovascular and cerebrovascular events, as well as total mortality 13, 14 The felodipine post-conversion blood pressure control was improved in our white population. Sixty-nine (87%) patients were controlled to DBP<90 mm Hg on nifedipine; when converted to felodipine, 74 (94%) patients were controlled to the Outcome Analysis of a Formulary Transition from Nifedipine to Felodipine at a Veterans Affairs Medical Center 
